Voters should care about this bill because it touches on the safety and regulation of a widely used medical procedure. Chemical abortions now account for over half of all abortions in the United States, so any changes in how these drugs are reviewed or regulated could have broad implications for reproductive healthcare access and public health information.

If this resolution passes and the FDA acts on its urging, it could lead to a reexamination of the known risks and benefits of chemical abortion drugs, potentially changing how they are prescribed, dispensed, or monitored. If the resolution does not pass or the FDA does not act on the urging, the current regulatory framework and public information regarding these drugs would remain unchanged, maintaining the status quo regarding their access and oversight.